| Description |
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer[1].
|
| Related Catalog |
|
| In Vitro |
Olinvacimab (0-1000 nM) 抑制 VEGF 与其受体 KDR 的结合，Kd 值为 0.23 nM[1]。 Olinvacimab 抑制 VEGF-165，VEGF-C 和 VEGF-D 与 VEGFR-2 的结合，IC50 分别为 8.7，6.3 和 7.0 nM[1]。 Olinvacimab (0.5-30 μg/mL；30 min) 抑制 VEGFR-2/KDR 和 ERK 的磷酸化[1]。 Olinvacimab (1，15，20 mg/mL；30 min) 抑制 VEGF 诱导的人脐静脉内皮细胞增殖[1]。 Olinvacimab (20 mg/mL；30 min) 抑制 VEGF 刺激的人脐静脉内皮细胞迁移[1]。 Olinvacimab (5，10，20 μg；20 h) 剂量依赖性的抑制血管形成并干扰管状结构[1]。 Olinvacimab (1 和 20 μg；6 d) 抑制 hVEGF165 诱导的大鼠主动脉环血管发芽[1]。 Western Blot Analysis[1] Cell Line: Human umbilical vein endothelial cell (HUVEC) line Concentration: 0.5, 1, 5, 10, 20 and 30 μg/mL Incubation Time: 30 min Result: Inhibited VEGF-induced phosphorylation of VEGFR-2 and ERK (downstream signaling molecule) in HUVECs.
|
| In Vivo |
Olinvacimab (100 ng；皮下注射，1 次) 抑制体内血管生成[1]。 Animal Model: Matrigel-implanted nude mice model[1] Dosage: 100 ng Administration: Subcutaneous injection; 100 ng, once Result: Inhibited the neovascularization induced by hVEGF165.
|
| References |
[1]. Lee WS, et al. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. MAbs. 2015;7(5):957-68.
|
